Executive Briefing: Biomarkers and beyond
This article was originally published in Scrip
In recent years, much has been written about the concept of personalised medicine, which has been defined as "a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose and treat disease". As far as drug treatment is concerned, this means that for each individual patient there will be an optimum drug that, administered in an appropriate dose and at the right time, will lead to the best possible outcome.
You may also be interested in...
The health care industry has come a long way in the past 35 years, although in some areas very little has changed. Recently retired In Vivo editor Peter Charlish has seen most of the major developments, and in his final feature, he looks back at some of the big stories in a reporting career that began in the early 1980s.
Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.
The market for minimally invasive weight loss devices will reach more than $290 million by 2021, according to a new report from Informa’s Meddevicetracker. Issues relating to laparoscopic adjustable gastric banding systems will result in a greater emphasis being placed on intragastric balloons, which will grow at twice the segment average.